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Tumor heterogeneity and the dynamic tumor immune
microenvironment have become important topics in the
field of cancer immunotherapy. The ability to noninva-
sively monitor immune cells in vivo via surface markers
on immune cell subsets using immuno-positron emis-
sion tomography (immuno-PET) is an attractive means
of visualizing both systemic and intratumoral alterations
in immune cell numbers and localization during experi-
mental immunotherapies. Due to the critical role of
tumor-infiltrating cytotoxic CD8+ T cells in anti-tumor
immune responses, a radiolabeled anti-CD8 antibody
fragment (cys-diabody) was developed for immuno-PET
detection of cytotoxic CD8+ T cells in vivo. The anti-
CD8 cys-diabody radiolabeled with 89Zr using the
bifunctional chelator deferoxamine-maleimide enabled
visualization of the spleen and lymph nodes in normal
mice; specificity was confirmed in CD8-blocking studies.
Next, anti-CD8 immuno-PET was shown to specifically
detect tumor-infiltrating lymphocytes in immunotherapy
models including agonistic antibody therapy (anti-CD137/
4-1BB) and checkpoint blockade antibody therapy (anti-
PD-L1). Balb/c mice bearing week old syngeneic CT26
colorectal tumors were treated with either anti-CD137 or
anti-PD-L1 antibody therapy and imaged at day 8 post-
therapy. All mice treated with anti-CD137 therapy demon-
strated tumor regression and increased anti-CD8
immuno-PET targeting in the tumors of mice treated with
anti-CD137 therapy compared to the tumor of untreated
mice. Ex vivo biodistribution confirmed enhanced
tumor uptake of anti-CD137 treated versus untreated
mice (15 ± 5.5 %ID/g versus 6.0 ± 0.83 %ID/g,
respectively). Anti-CD8 immuno-PET of untreated mice
demonstrated a rim of activity around the tumor while
anti-CD137 treated mice demonstrated enhanced intratu-
moral uptake. The increase in CD8+ tumor-infiltrating
lymphocytes was validated by both flow cytometry and
immunohistochemistry. About 30% of mice treated with
anti-PD-L1 therapy demonstrated tumor regression and
were grouped into non-responders (average tumor dia-
meter > 8mm) and responders (average tumor diameter <
8mm). Anti-PD-L1 non-responders and responders had
tumor anti-CD8 immuno-PET uptake of 6.4 ± 1.5 %ID/g
and 11.27 ± 2.7 %ID/g as determined from ex vivo biodis-
tribution analysis, respectively, demonstrating enhanced
CD8+ T cell infiltration in responding mice that was con-
firmed by flow cytometry. Anti-CD8 immuno-PET was
successful in the noninvasive detection of tumor-infiltrating
CD8+ T cells in two differing antibody-based immunother-
apy strategies that have shown promise in the clinic.
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